NovaBridge Biosciences (NBP) Earnings History
Annual and quarterly earnings data from 2017 to 2024
Loading earnings history...
NBP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NBP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | 100.0% | -11395.1% | -32674.0% |
| 2022 | - | - | - |
| 2021 | 47.3% | -2353.1% | -2648.7% |
| 2020 | 100.0% | 10.1% | 30.5% |
Download Data
Export NBP earnings history in CSV or JSON format
Free sign-in required to download data
NovaBridge Biosciences (NBP) Earnings Overview
As of May 8, 2026, NovaBridge Biosciences (NBP) reported trailing twelve-month net income of -$25M, reflecting +74.7% year-over-year growth. The company earned $-0.24 per diluted share over the past four quarters.
Looking at the long-term picture, NBP's historical earnings data spans multiple years. The company achieved its highest annual net income of $471M in fiscal 2020.
NovaBridge Biosciences is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), NBP has comparable earnings metrics. Compare NBP vs RCUS →
NBP Earnings vs Peers
Earnings metrics vs comparable public companies
NBP Historical Earnings Data (2017–2024)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$162M | +88.9% | -$375M | $-4.46 | - | - |
| 2023 | -$1.47B | +41.5% | -$511M | $-17.62 | -32674.0% | -11395.1% |
| 2022 | -$2.51B | -7.5% | -$366M | $-30.38 | - | - |
| 2021 | -$2.33B | -595.1% | -$2.07B | $-30.68 | -2648.7% | -2353.1% |
| 2020 | $471M | +131.7% | $156M | $6.90 | 30.5% | 10.1% |
| 2019 | -$1.49B | -268.6% | -$1.46B | $-25.53 | -4950.0% | -4883.2% |
| 2018 | -$403M | -35.1% | -$439M | $-6.92 | -749.0% | -815.6% |
| 2017 | -$298M | - | -$281M | $-5.13 | -2580.8% | -2431.2% |
See NBP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBP — Frequently Asked Questions
Quick answers to the most common questions about buying NBP stock.
Is NBP growing earnings?
NBP EPS is $-0.24, with earnings growth accelerating to +74.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-25M.
What are NBP's profit margins?
NovaBridge Biosciences net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are NBP's earnings?
NBP earnings data spans 2017-2024. The accelerating earnings trend is +74.7% YoY. Historical data enables comparison across business cycles.